Compounds that act on mechanisms associated with resistance of glioblastoma stem cells show efficacy in mouse models.
References
Bao, S. et al. Nature 444, 756–760 (2006).
Piccirillo, S.G. et al. Nature 444, 761–765 (2006).
Stupp, R. et al. N. Engl. J. Med. 352, 987–996 (2005).
Singh, S.K. et al. Nature 432, 396–401 (2004).
Phillips, T.M., McBride, W.H. & Pajonk, F. J. Natl. Cancer Inst. 98, 1777–1785 (2006).
Hegi, M.E. et al. N. Engl. J. Med. 352, 997–1003 (2005).
Potti, A. et al. Nat. Med. 12, 1294–1300 (2006).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Stupp, R., Hegi, M. Targeting brain-tumor stem cells. Nat Biotechnol 25, 193–194 (2007). https://doi.org/10.1038/nbt0207-193
Issue Date:
DOI: https://doi.org/10.1038/nbt0207-193
- Springer Nature America, Inc.
This article is cited by
-
Synergistic inhibition of tumor growth by combination treatment with drugs against different subpopulations of glioblastoma cells
BMC Cancer (2017)
-
Hypothermia Stimulates Glioma Stem Spheres to Spontaneously Dedifferentiate Adjacent Non-stem Glioma Cells
Cellular and Molecular Neurobiology (2015)
-
CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells
Oncogene (2010)
-
Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins
Oncogene (2008)